How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019 – Market Realist

408

How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019  Market Realist

The launch of Mylan’s Wixela Inhub, the generic version of Advair, was a key factor driving down GlaxoSmithKline’s Established Pharmaceuticals revenues.

RELATED ARTICLESMORE FROM AUTHOR